M Venturini

Summary

Country: Italy

Publications

  1. ncbi Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer
    M Venturini
    Divisione di Oncologia Medica 1, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
    J Clin Oncol 14:3112-20. 1996
  2. ncbi Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia
    L Del Mastro
    Divisione di Oncologia Medica I, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
    J Clin Oncol 15:2715-21. 1997
  3. ncbi Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients
    M Esposito
    Pharmacotoxicology Laboratory, Department of Preclinical Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
    J Clin Oncol 17:1132. 1999
  4. ncbi Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity
    M Venturini
    Department of Medical Oncology I and Pharmacotoxicology Laboratory, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
    J Clin Oncol 18:2116-25. 2000
  5. ncbi Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: findings from two consecutive trials of Gruppo Oncologico Nord-Ovest-Mammella Intergruppo (GONO-MIG) Group
    L Del Mastro
    Oncologia Medica A, Istituto Nazionale per Ricerca sul Cancro, Largo Rosanna Benzi, Genova, Italy
    Ann Oncol 19:299-307. 2008
  6. ncbi Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer
    M Venturini
    Division of Medical Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
    Breast Cancer Res Treat 95:45-53. 2006
  7. ncbi Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer
    M Venturini
    Division of Medical Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
    Ann Oncol 13:546-52. 2002
  8. ncbi Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients
    M Venturini
    Division of Medical Oncology I, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
    Ann Oncol 12:1097-106. 2001
  9. ncbi Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications
    L Del Mastro
    Oncologia Medica 1, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
    Breast Cancer Res Treat 43:183-90. 1997
  10. pmc Phase I study of simultaneous dose escalation and schedule acceleration of cyclophosphamide-doxorubicin-etoposide using granulocyte colony-stimulating factor with or without antimicrobial prophylaxis in patients with small-cell lung cancer
    A Ardizzoni
    Division of Medical Oncology I, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
    Br J Cancer 74:1141-7. 1996

Collaborators

Detail Information

Publications24

  1. ncbi Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer
    M Venturini
    Divisione di Oncologia Medica 1, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
    J Clin Oncol 14:3112-20. 1996
    ..The main objective of this study was to investigate the efficacy of dexrazoxane, given at a dose ratio of 10:1 against epirubicin cardiotoxicity...
  2. ncbi Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia
    L Del Mastro
    Divisione di Oncologia Medica I, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
    J Clin Oncol 15:2715-21. 1997
    ..The aim of this study was to evaluate the ability of EPO in preventing the development of clinically significant anemia in patients treated with chemotherapy...
  3. ncbi Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients
    M Esposito
    Pharmacotoxicology Laboratory, Department of Preclinical Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
    J Clin Oncol 17:1132. 1999
    ..To investigate whether paclitaxel and docetaxel influence the pharmacokinetics and metabolism of epirubicin...
  4. ncbi Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity
    M Venturini
    Department of Medical Oncology I and Pharmacotoxicology Laboratory, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
    J Clin Oncol 18:2116-25. 2000
    ..We investigated whether reversing the sequence of epirubicin and paclitaxel affects the pattern or degree of toxicity and pharmacokinetics...
  5. ncbi Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: findings from two consecutive trials of Gruppo Oncologico Nord-Ovest-Mammella Intergruppo (GONO-MIG) Group
    L Del Mastro
    Oncologia Medica A, Istituto Nazionale per Ricerca sul Cancro, Largo Rosanna Benzi, Genova, Italy
    Ann Oncol 19:299-307. 2008
    ..We analyzed the outcome of both pre- and postmenopausal women who entered two randomized trials (Gruppo Oncologico Nord-Ovest-Mammella Intergruppo studies) on adjuvant chemotherapy and received either concomitant or sequential TAM...
  6. ncbi Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer
    M Venturini
    Division of Medical Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
    Breast Cancer Res Treat 95:45-53. 2006
    ..7 months (95% CI, 11.6-19.0 months). In light of the cardiotoxicity experienced during this study, we currently recommend that this combination be used only in controlled clinical trials under vigilant cardiac monitoring...
  7. ncbi Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer
    M Venturini
    Division of Medical Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
    Ann Oncol 13:546-52. 2002
    ..This phase I study evaluated the addition of capecitabine to epirubicin/docetaxel combination therapy as first-line treatment for advanced breast cancer...
  8. ncbi Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients
    M Venturini
    Division of Medical Oncology I, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
    Ann Oncol 12:1097-106. 2001
    ..To determine the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of docetaxel in combination with fixed doses of epirubicin...
  9. ncbi Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications
    L Del Mastro
    Oncologia Medica 1, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
    Breast Cancer Res Treat 43:183-90. 1997
    ..In order to gain insight into the role of DIA, we reviewed all published data addressing the issue of DIA as a prognostic factor...
  10. pmc Phase I study of simultaneous dose escalation and schedule acceleration of cyclophosphamide-doxorubicin-etoposide using granulocyte colony-stimulating factor with or without antimicrobial prophylaxis in patients with small-cell lung cancer
    A Ardizzoni
    Division of Medical Oncology I, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
    Br J Cancer 74:1141-7. 1996
    ..65-1.80 for a maximum of 3-4 courses. The role of antimicrobial prophylaxis in this setting deserves to be investigated further...
  11. ncbi Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients
    G Lunardi
    Department of Pharmacology Pharmacotoxicology Laboratory, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
    Ann Oncol 14:1222-6. 2003
    ..The mechanism by which it occurs is as yet unknown. The aim of this study was to evaluate whether trastuzumab modifies the pharmacokinetics of epirubicin and its metabolites...
  12. ncbi Toremifene as a substitute for adjuvant tamoxifen in breast cancer patients
    G Bertelli
    Medical Oncology Division and University, National Cancer Institute, Genova, Italy
    Anticancer Res 20:3659-61. 2000
    ..Clinical trials of adjuvant toremifene vs. tamoxifen in breast cancer patients are ongoing. This study aimed to evaluate the short-term effects of changing from adjuvant tamoxifen to toremifene...
  13. pmc Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast cancer
    A Ardizzoni
    Department of Medical Oncology I, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
    Br J Cancer 69:385-91. 1994
    ..Accelerated CEF + GM-CSF is a moderately dose-intensive regimen that can be administered in an outpatient clinic and is associated with a high objective response...
  14. ncbi Predicting mood disorders in breast cancer patients
    G Morasso
    Department of Psychology, National Cancer Institute, L go R Benzi, 10, 16132, Genova, Italy
    Eur J Cancer 37:216-23. 2001
    ....
  15. ncbi [Use of erythropoietin in oncology]
    R Rosso
    Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
    Tumori 83:S26-30. 1997
    ..The preventive use of erythropoietin is still under investigation. Further studies should identify subsets of patients and types of chemotherapy in which the prevention of anemia could be cost/effective...
  16. ncbi Taxane-containing chemotherapy in the treatment of early breast cancer patients
    M Clavarezza
    Oncologia Medica A, National Cancer Research Institute, Genova, Italy
    Ann Oncol 17:vii22-6. 2006
    ..In conclusion, taxane-based adjuvant chemotherapy is a standard option for most early breast cancer patients with node-positive disease. No sufficient and dedicated data are available in node-negative disease...
  17. ncbi Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients
    L Del Mastro
    Oncologia Medica, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
    Ann Oncol 17:74-8. 2006
    ..This phase II study aimed to assess the activity of such a method in young, breast cancer patients undergoing adjuvant chemotherapy...
  18. ncbi [Mobilization of peripheral blood stem cells with conventional chemotherapy]
    M Venturini
    Divisione di Oncologia Medica 1, Istituto Nazionale per la Ricerca sul Cancro, Genova
    Tumori 82:S14-8. 1996
    ..The choice between standard and high-dose chemotherapy can be based on patients characteristic and disease status...
  19. ncbi Impact of two different dose-intensity chemotherapy regimens on psychological distress in early breast cancer patients
    L Del Mastro
    Department of Medical Oncology, National Cancer Research Institute, Genova, Italy
    Eur J Cancer 38:359-66. 2002
    ..Final results of the randomised trial will indicate whether such higher adverse effects of the dose-intensive regimen are counterbalanced by a higher efficacy of the experimental treatment in terms of survival...
  20. ncbi High-dose chemotherapy shows a dose-dependent toxicity to bone marrow osteoprogenitors: a mechanism for post-bone marrow transplantation osteopenia
    A Banfi
    Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
    Cancer 92:2419-28. 2001
    ....
  21. ncbi A pilot study of mitomycin, ifosfamide and cisplatin as outpatient combination chemotherapy for advanced non-small cell lung cancer
    G L Mariani
    Divisione di Oncologia Medica, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
    Tumori 77:511-3. 1991
    ..8%; 36.8% of patients had stable disease, and 15.7% progressed during treatment. Median duration was 8.7 months and median survival was 11 months. Toxicity was low and easily manageable on an out-patient basis...
  22. ncbi Influence of alternate sequences of epirubicin and docetaxel on the pharmacokinetic behaviour of both drugs in advanced breast cancer
    G Lunardi
    Servizio di Farmacologia e Neuroscienze, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
    Ann Oncol 13:280-5. 2002
    ..e. when paclitaxel is administered as first drug). The aim of this study was to determine whether these sequence-dependent pharmacological effects were also evident when epirubicin was combined with docetaxel...
  23. ncbi A preliminary clinical study of cyclophosphamide with reduced glutathione as uroprotector
    M T Nobile
    Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
    Tumori 75:257-8. 1989
    ..2 up to 1.6 g/m2 (1-h infusion). GSH was well tolerated and did not produce unexpected toxicity. The lack of bladder damage, including microscopic hematuria, supports the protective role of this thiol compound...
  24. ncbi Rational development of capecitabine
    M Venturini
    Divisione Oncologia Medica, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
    Eur J Cancer 38:3-9. 2002
    ..This established an intermittent regimen of capecitabine 1250 mg/m2 twice daily for 14 days followed by a 7-day rest period as the most appropriate regimen for further clinical development...